PTO/SB/08A (08-00)

Approved to use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Please type a plus sign (+) inside this box Substitute for form 1449A/PTO

PATENT &

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of

Complete if Kn wn				
Application Number	09/927,121			
Filing Dat	August 10, 2001			
First Named Invent r	Gold, D.			
Group Art Unit	1645			
Examiner Name	To Be Assigned			
Attorney Docket Number	032077.0003.UTL			

				U.S. PATENT DOCU	MENTS	
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Number	Cif known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant
JWL	AA	4,816,249		Levy, et al.	03-28-1989	Figures Appear

				FUREIGN P	ATENT DOCUMEN	ITS		
Examiner	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines.	_
Initials	No.	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>3</sup> (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
								_
1								丄

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
M	AB	BENVENUTI, F., et al., "Anti-Idiotypic DNA Vaccines for Lymphoma Immunotherapy Require the Presence of Both Variable Region Genes for Tumor Protection" <i>Gene Therapy</i> 7(7):605-611 (2000)	
OHE	AC	SELMAYR, M., et al., "B-Cell Lymphoma Idiotypes Chimerized by Gene Targeting Can Induce Tumor Immunity," Cancer Gene Therapy 7(3): 501-506 (2000)	_
5HL	AD	VEELKEN, H., et al., "Rapid Expression Cloning of B Cell Lymphoma-Derived Immunoglobulin Genes for Anti-Idiotypic Vaccination and Functional Analyses of Fab-Fragments," <i>Blood</i> 90(10): 515A (1997)	

RECEIVED

OCT 0 8 2002

TECH CENTER 1600/2900

Examiner Signature	Date Considered X/X/o >
	Considered   ATA(O)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.